Gene · 9733
SART3: spliceosome associated factor 3, U4/U6 recycling protein
12 sourcesgene-search-2026-11-11-0.2.0
Cite this record
ConductScience Library. SART3: spliceosome associated factor 3, U4/U6 recycling protein. Genes, record 9733. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/9733
On this page
Gene
Proteins1
Reviewed human proteins whose Swiss-Prot entry states the gene.
| UniProt entry | Protein | Length | Structures | Gene stated in |
|---|---|---|---|---|
| Q15020 | Spliceosome associated factor 3, U4/U6 recycling protein | 963 | 9 | Ensembl, GeneID, HGNC |
Source UniProt
Patents61
Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.
| Publication | Published | SEQ ID NO | Protein | Source |
|---|---|---|---|---|
| JP 2026004568 A | 2026-01-14 | 65385 | Q15020 | Espacenet |
| EP 4650780 A2 | 2025-11-19 | 16603 | Q15020 | Espacenet |
| EP 4641201 A2 | 2025-10-29 | 20486 | Q15020 | Espacenet |
| JP 2025517969 A | 2025-06-12 | 20486 | Q15020 | Espacenet |
| JP 2025517970 A | 2025-06-12 | 16603 | Q15020 | Espacenet |
| EP 4487869 A2 | 2025-01-08 | 438 | Q15020 | Espacenet |
| JP 2024509935 A | 2024-03-05 | 1157 | Q15020 | Espacenet |
| KR 1020240027895 A | 2024-03-04 | 626 | Q15020 | Espacenet |
| JP 2023036863 A | 2023-03-14 | 626 | Q15020 | Espacenet |
| US 11446398 B2 | 2022-09-20 | 83785 | Q15020 | Espacenet |
1 to 10 of 61
See all 61 patentsDrugs0
Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.
None in this release.
Trials0
Trials of those drugs. A trial joins the gene only through a drug that acts on it.
None in this release.
NIH grants1,075
NIH grants whose papers are about the gene, through NIH's grant-paper links.
| Grant | Title | SART3 papers | Newest fiscal year |
|---|---|---|---|
| P30CA016672 | Cancer Center Support Grant | 12 | 2025 |
| P30CA068485 | Cancer Center Support Grant | 6 | 2025 |
| P30CA021765 | Cancer Center Support Grant (CCSG) | 5 | 2025 |
| P30CA008748 | Cancer Center Support Grant | 4 | 2025 |
| P30CA013330 | Cancer Center Support Grant | 4 | 2025 |
| R01AG011085 | Ubiquitin‐mediated proteolysis and cell cycle control | 4 | 2025 |
| P30AI027763 | UCSF-Bay Area Center for AIDS Research | 3 | 2025 |
| P30CA006973 | Regional Oncology Research Center | 3 | 2025 |
| P30CA060553 | The Robert H. Lurie Comprehensive Cancer Center | 3 | 2025 |
| P30CA091842 | Cancer Center Support Grant | 3 | 2025 |
1 to 10 of 1,075Source NIH's project files
See all 1,075 nih grantsPapers1,339
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Targeting ADAR1 p150 triggers tumor inhibition and antitumor immunity to overcome immunotherapy resistance. | iScience | 2026 | 42221825 | PubTator, text mining | PubMed |
| A bioinformatics pipeline for the design of a SART3-targeted cancer vaccine with enhanced immunogenicity. | Genomics Inform | 2026 | 42067955 | PubTator, text mining | PubMed |
| LncRNA LASTR promotes TGF-β signalling and EMT in HNSCC by enhancing TGFβR1 expression by suppressing biogenesis of miR-34a and acting as its ceRNA. | Cell Signal | 2026 | 41812719 | PubTator, text mining | PubMed |
| Rabies lyssavirus phosphoprotein possesses RNA duplex-unwinding activities. | Mol Ther Nucleic Acids | 2026 | 41783789 | PubTator, text mining | PubMed |
| Construction and initial validation of key gene network for progesterone resistance in endometrial cancer based on genome-wide CRISPR screening. | Sci Rep | 2026 | 41775739 | PubTator, text mining | PubMed |
| TIE2-positive cells in the nucleus pulposus with a purpose: the who, what and why. | J Biomed Sci | 2026 | 41772594 | PubTator, text mining | PubMed |
| Research Progress on the Biological Function, Disease-Driving Mechanism and Clinical Targeting Strategies of G3BP2. | Molecules | 2026 | 41752399 | PubTator, text mining | PubMed |
| Advances in Breast Cancer Research: Immunological, Pathological, and Pharmacological Perspectives for Improving Patient Outcomes. | Int J Mol Sci | 2026 | 41752040 | PubTator, text mining | PubMed |
| Identification of two novel MVD mutations and one novel FDPS mutation in Chinese patients with porokeratosis. | Front Med (Lausanne) | 2026 | 41737384 | PubTator, text mining | PubMed |
| Advances in T cell-based immunotherapy for osteosarcoma. | Front Immunol | 2026 | 41727478 | PubTator, text mining | PubMed |
1 to 10 of 1,339
See all 1,339 papersSources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this gene from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/genes/v1/9733
GET https://conductscience.org/api/genes/v1/9733/patents?page=2